Pharming Group (PHAR) Q4 2025: Joenja Surges 53% as U.S. Drives 75% of Growth

2026-03-12 | By EarningsIQ Research

Pharming Group capped 2025 with a decisive operational and financial turnaround, propelled by double-digit growth from both Ruconest and Joenja. The company’s transformation from single-product to diversified rare disease player is now visible in both its profit profile and pipeline momentum. Investors face a year of key clinical readouts and international expansion catalysts, while management signals discipline in capital allocation and cost control.

Summary

• Joenja’s U.S. Momentum: U.S. patient growth and identification are accelerating, underpinning Joenja’s global expansion.
• Pipeline Inflection: Late-stage readouts and regulatory milestones in 2026 could reshape Pharming’s addressable market.
• Cost Discipline: Operating leverage and targeted R&D spend support a durable shift to profitability.

Performance Analysis

Pharming delivered a robust finish to 2025, with both Ruconest, acute HAE therapy, and Joenja, APDS treatment, posting double-digit annual growth. Ruconest’s 26% global growth was driven by high-frequency HAE patient demand, even as new entrants arrived in the U.S. market. Joenja’s 53% Q4 surge marked a new milestone, with global annual revenue surpassing $50 million for the first time, reflecting both U.S. and international uptake.

Profitability inflected sharply: the company swung to $26 million in operating profit for the year, a reversal from 2024’s loss, as disciplined cost management, a 20% G&A headcount reduction, and tight control of marketing and sales spend offset R&D ramp-up. Operating cash flow of $55 million and a $12 million year-end cash increase further underscore improved commercial execution and capital efficiency, even after the $68 million Ableva acquisition.

• Joenja Growth Engine: 75% of Joenja’s anticipated 2026 growth is expected from the U.S., with international launches providing incremental upside.
• Ruconest Resilience: Despite market churn from new therapies, patient return rates and new enrollments confirm its niche in high-attack HAE patients.
• Margin Stability: Gross margin held at 88% even after milestone payments, reflecting commercial scale and product mix stability.

Management’s 2026 guidance reflects confidence in both commercial momentum and cost containment, while factoring in Q1 inventory drawdowns and a staged ex-U.S. rollout for Joenja.

Executive Commentary

Strategic Positioning

1. Joenja’s U.S. and Global Expansion

Joenja, oral APDS therapy, is positioned as Pharming’s primary growth driver, with 70%–75% of 2026 growth expected from the U.S. The company has increased its pool of identified U.S. patients by more than double YoY, laying groundwork for future market penetration. Internationally, launches in the U.K. and upcoming approvals in Japan and Europe are set to provide incremental growth, with >80 patients already on early access outside the U.S.

2. Ruconest’s Durable Niche

Ruconest, recombinant C1 esterase inhibitor, continues to anchor Pharming’s revenue base. Despite new oral competitors, Ruconest’s rapid, reliable relief for high-attack HAE patients has led to patient returns and new prescriber additions. The acute, high-frequency segment remains relatively insulated, with management projecting mid-single-digit growth at the midpoint for 2026.

3. Pipeline Readouts and Regulatory Catalysts

Key late-stage pipeline assets, including laniolisib for broader primary immune deficiencies and napasomone for mitochondrial diseases, are approaching value inflection points. Phase II laniolisib data is expected in H2 2026, and napasomone’s pivotal study will complete enrollment this year, with data in 2027. Regulatory clarity for Joenja’s pediatric label expansion in the U.S. (ages 4–11) is a near-term catalyst, with a Type A FDA meeting scheduled for March.

4. Financial Discipline and Capital Allocation

Cost structure optimization, highlighted by a 20% G&A reduction and stable marketing spend, is enabling Pharming to fund >$60 million in incremental R&D without margin erosion. Management’s approach to M&A is measured, focused on value-accretive pipeline additions rather than defensive dealmaking.

5. Commercial Execution and Market Access

Pharming’s commercial teams have demonstrated the ability to execute launches and access strategies across geographies. The company is building infrastructure and reimbursement pathways in Europe, Japan, and Canada, with tailored physician engagement and diagnostic initiatives to accelerate patient conversion post-approval.

Key Considerations

2025 was a pivotal year for Pharming, marking a shift from single-product dependence to a diversified revenue and pipeline base. The commercial strategy now hinges on maximizing Joenja’s penetration in APDS and adjacent PIDs, while sustaining Ruconest’s leadership in acute HAE.

Key Considerations:

• Joenja’s International Ramp: Regulatory and reimbursement timelines will dictate the pace of ex-U.S. revenue contribution in 2026 and beyond.
• Pediatric Label Expansion: U.S. approval for Joenja in children aged 4–11 is a major near-term growth lever, with 52 eligible patients already identified for rapid conversion.
• Inventory Dynamics: Q1 Ruconest revenue is expected to dip due to inventory drawdown, a temporary effect as channel inventory normalizes.
• Pipeline Optionality: Success in laniolisib’s broader PID indications could expand Pharming’s addressable market by 5–26x versus APDS alone.
• Capital Allocation Discipline: Management’s cost controls and selective approach to M&A reduce risk of margin compression as pipeline investments scale.

Risks

Regulatory approvals for Joenja’s pediatric and ex-U.S. launches remain uncertain, with potential for delays or additional data requirements. Competitive intensity in HAE and APDS markets, particularly from new oral therapies, could pressure growth and pricing. Pipeline execution risk is material, as late-stage readouts underpin future value creation. Currency fluctuations and reimbursement negotiations add further unpredictability to international revenue realization.

Forward Outlook

For Q1 2026, Pharming guided to:

• Ruconest U.S. revenue impacted by 7%–9% inventory drawdown YoY
• Joenja growth to accelerate, with U.S. as primary driver

For full-year 2026, management reaffirmed:

• Total revenue of $405–$425 million (8%–13% YoY growth)
• Operating expenses of $330–$335 million, with >$60 million incremental R&D
• Gross margin guidance at 90% (10% COGS)

Management highlighted:

• Ex-U.S. Joenja launches and regulatory milestones as key growth catalysts
• Financial discipline and cash flow to fully fund pipeline and pre-launch activities

Takeaways

Pharming’s 2025 results validate its transition to a high-growth, multi-asset rare disease company with durable profitability and a robust pipeline.

• Joenja’s U.S. and international ramp will determine the pace of revenue mix shift, with pediatric and geographic expansion as major levers.
• Ruconest’s resilience in the face of new competition supports a stable cash base for pipeline investment and commercial flexibility.
• Investors should monitor late-stage pipeline data, regulatory outcomes, and the company’s ability to convert early access patients to paid therapy as key forward indicators.

Conclusion

Pharming enters 2026 with clear commercial momentum, an expanding pipeline, and a disciplined financial framework. The company’s ability to convert clinical and regulatory milestones into commercial results will be critical in sustaining its rare disease leadership ambitions.

Industry Read-Through

Pharming’s trajectory signals that rare disease biotechs with validated commercial assets and disciplined cost structures can achieve durable profitability and fund late-stage innovation without dilutive capital raises. The rapid identification and conversion of ultra-rare patient populations, combined with international launch execution, sets a new bar for rare disease commercialization. Competitors in HAE and PID spaces must contend with both entrenched therapies and the need for differentiated value propositions, especially as payers and regulators demand real-world evidence and cost-effectiveness. Pipeline optionality and operational discipline are likely to be key differentiators for sector leaders in 2026 and beyond.

PHAR Healthcare Biotechnology Rare disease Commercialization Pipeline Profitability